Descrizione del progetto
Intelligenza artificiale per fornire terapie intelligenti negli ospedali
Il consorzio europeo AIDPATH è volto a consentire e rafforzare la medicina personalizzata di prossima generazione con cellule immunitarie geneticamente ingegnerizzate in ospedali europei, utilizzando la tecnologia dell’IA. La forma esemplare di realizzazione delle cellule immunitarie ingegnerizzate geneticamente di AIDPATH sarà rappresentata dalle cellule T, modificate per esprimere un recettore dell’antigene chimerico (CAR-T, Chimeric Antigen Receptor T) di sintesi, che già costituiscono un inedito trattamento rivoluzionario in ematologia e oncologia. AIDPATH applicherà la tecnologia dell’IA per integrare dati e biomarcatori specifici per il paziente nella terapia CAR-T e per ottimizzare la programmazione e la pianificazione di risorse al fine di ridurre i costi e l’utilizzo di risorse ospedaliere. I membri del consorzio sono pronti per il coinvolgimento in un proficuo dialogo con legislatori e pazienti, al fine di verificare l’accoglimento e la rapida adozione del sistema da parte di ospedali e industrie d’Europa.
Obiettivo
AIDPATH (Artificial Intelligence-driven, Decentralized Production for Advanced Thera-pies in the Hospital) is a high-energy EU consortium, dedicated to enable and to augment the next-generation of personalized medicine at EU hospitals through the use of AI tech-nology. The exemplary embodiment of gene-engineered immune cells in AIDPATH will be T cells expressing a synthetic chimeric antigen receptor (CAR-T). These cells are already a revolutionary novel treatment in hematology and oncology, and will also be useful for treating infections and autoimmune diseases. Conventional CAR-T therapy is complicated by complex logistics from centralized manufacturing facilities, inflexible manufacturing and clinical use schemes that disregard patient and cell characteristics, thus limiting patient access and therapeutic outcome.
AIDPATH will apply top-notch AI technology to integrate patient-specific data and biomarkers in CAR-T therapy, and apply flexible manufacturing schemes to obtain CAR-T cell products with optimal fitness and anti-tumor potency. AI technology will be applied in pre- and in-process controls to reduce cost and hospital resource utilization and to augment patient access. AIDPATH will establish a role model that integrates the hospital in a smart manner, incorporating aspects of logistics, capacity planning, data management and cybersecurity by design. The project is designed to enable smart ‘bedside’ provision of personalized treatments and to accomplish end-to-end automation of hospital-based CAR-T manufacture. A key deliverable in AIDPATH will be an integrated cyberphysical infrastructure for rapid dissemination of the ‘smart CAR-T manufacturing and clinical use’ concept to hospitals throughout the EU.
AIDPATH brings together a world-class consortium to address these challenges, consisting of key opinion leaders in science and translational medicine, innovative SMEs and commercial partners, patient advocates, policy makers and regulatory experts.
Campo scientifico
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health sciencesclinical medicineoncology
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesclinical medicinehematology
- natural sciencescomputer and information sciencescomputer security
Parole chiave
Programma(i)
Meccanismo di finanziamento
IA - Innovation actionCoordinatore
80686 Munchen
Germania